Abstract: The present invention relates to efficient synthetic processes useful in the preparation of uridine, which is useful in the production of nucleosides and nucleotides that may be active as antiviral agents, as well as compositions and methods thereof.

Abstract: The present invention relates to efficient synthetic processes useful in the preparation of antiviral nucleosides, particularly uridine 4-oxime 5?-(2-methylpropanoate) {(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate and pharmaceutically acceptable salts, derivatives, tautomers, isomers, and prodrugs of, which may be active as antiviral agents, as well as compositions and methods thereof. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

Abstract: The invention is related to the preparation of protected piperidine carboxylates suitable for use as intermediates that lead, via a series of additional process steps, including a sulfation of a hydroxy urea compound, to the preparation of the beta lactamase inhibitor (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide.

Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.

Abstract: The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that may be useful as synthetic intermediates in the process of the invention.

Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.

Abstract: The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that may be useful as synthetic intermediates in the process of the invention.

Abstract: The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that are useful as synthetic intermediates in the process of the invention.

Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase, HIV replication and the treatment of human immunodeficiency virus infection in humans.

Abstract: Disclosed is a transition metal complex represented by the following formula (1): (wherein: M represents a transition metal element; K represents an uncharged monodentate or bidentate ligand; L represents a monodentate or bidentate monoanionic or dianionic ligand; m and o represent an integer from 0 to 5; n represents an integer from 1 to 3; p represents an integer from 0 to 4; W— represents a counterion; and Y1 to Y4, R1, and R2 each independently represent a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aralkyl group, a heteroaryl group, an alkenyl group, an alkynyl group, or an alkoxy group).

Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.

Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.

Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase, HIV replication and the treatment of human immunodeficiency virus infection in humans.

Abstract: The transition metal complex is represented by Formula (1) [where M represents a transition metal element; K and L each represent a monodentate or bidentate ligand; m and o each represent an integer from 0 to 5; n represents an integer from 1 to 3; X, Y, R1, R2, and R4 each represent a hydrogen atom, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, alkenyl, alkynyl, or alkoxy; R3 represents a hydrogen atom, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, alkenyl, alkynyl, aryloxy, or alkoxy having two or more carbon atoms; and A represents alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, alkenyl, alkynyl, or alkoxy].

Abstract: Disclosed is a transition metal complex represented by the following formula (1): (wherein M represents a transition metal element; K represents an uncharged monodentate or bidentate ligand; L represents a monodentate or bidentate monoanionic or dianionic ligand; m and o represent an integer from 0 to 5; n represents an integer from 1 to 3; p represents an integer from 0 to 4; W— represents a counterion; and Y1 to Y4, R1, and R2 each independently represent a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aralkyl group, a heteroaryl group, an alkenyl group, an alkynyl group, or an alkoxy group).

Abstract: A luminescent material includes a transition metal complex which comprises any one of Ir, Os, and Pt as a central metal; and at least one of a carbene ligand and a silylene ligand. The carbene ligand includes a boron atom in a skeleton thereof. The carbene ligand is neutral or monoanionic. The carbene ligand is monodentate, bidentate, or tridentate. The silylene ligand includes a boron atom in a skeleton thereof. The silylene ligand is neutral or monoanionic. The silylene ligand is monodentate, bidentate, or tridentate.

Abstract: A compound of the present invention is represented by the following formula (1): (where: R1 and R2 represent, independently, a substitutable C1 to C20 aliphatic hydrocarbon group; and R3 through R14 represent, independently, one of a hydrogen atom, a halogen atom, a substitutable aliphatic hydrocarbon group, and a substitutable aromatic hydrocarbon group). It is therefore possible to provide a novel compound which can be used as an organic semiconductor material.

Abstract: An enzyme electrode having excellent sensitivity, excellent stability, and a longer operating life, and an enzyme sensor using the enzyme electrode are provided. The enzyme electrode includes an electrode 2, a mesoporous silica material 3 formed on the electrode 2, and enzyme 4 immobilized in a small cavity of the mesoporous silica material 3. The size of the small cavity of the mesoporous silica material 3 is set to be 0.5 to 2.0 times the size of the enzyme 4.